2016
Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors
Hong J, Kwon Y, Kim I. Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors. Expert Opinion On Drug Metabolism & Toxicology 2016, 13: 183-192. PMID: 27690667, DOI: 10.1080/17425255.2017.1244265.Peer-Reviewed Original ResearchConceptsErectile dysfunctionClinical efficacyEvidence-based clinical efficacyTreatment of EDNon-urological conditionsDrug-related toxicityFirst-line drugsType 5 inhibitorsPhosphodiesterase-5 inhibitorsNew clinical usesChronic administrationBasic science articlesNeuroprotective roleClinical trialsPDE5IsBeneficial effectsClinical usesFurther studiesPharmacodynamicsPharmacokineticsEfficacyInhibitorsImpactful studiesBroad spectrumPDE5i
2015
Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer
Han C, Patel R, Kim I. Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer. Expert Opinion On Drug Metabolism & Toxicology 2015, 11: 967-975. PMID: 25936418, DOI: 10.1517/17425255.2015.1041918.Peer-Reviewed Original ResearchConceptsCastration-resistant prostate cancerMetastatic castration-resistant prostate cancerAbiraterone acetateMetastatic CRPCProstate cancerPhase III trialsBetter patient selectionHigh-level evidenceRisk of hypertensionDrug resistance patternsCurrent clinical challengesIntratumoral androgensOverall tolerabilityIII trialsPatient selectionClinical efficacySafety profileDevelopment of resistanceTreatment modalitiesDisease progressionTargeted therapyAndrogen sourceClinical challengeAndrogen signalingCYP 17
2014
Primary Androgen Deprivation Therapy for Prostate Cancer in Koreans: A Retrospective Multicenter Study
Seo W, Kang P, Kim T, Moon K, Chung J, Lee D, Kim I, Min K, Chung J, Kim W, Kang D. Primary Androgen Deprivation Therapy for Prostate Cancer in Koreans: A Retrospective Multicenter Study. The World Journal Of Men's Health 2014, 32: 159-166. PMID: 25606565, PMCID: PMC4298819, DOI: 10.5534/wjmh.2014.32.3.159.Peer-Reviewed Original ResearchPrimary androgen deprivation therapyAndrogen deprivation therapyAdvanced prostate cancerProstate cancerDeprivation therapyDefinitive therapyMetastatic stageMedian pretreatment PSA levelBetter progression-free survivalProstate-specific antigen progressionPSA progression ratePretreatment PSA levelCharacteristics of patientsProgression-free survivalRetrospective multicenter studyMedian survival timeHigher clinical stageAndrogen blockadeMedical comorbiditiesPSA progressionPSA changePSA levelsClinical factorsMedian ageClinical efficacy